Patents by Inventor David G. Winkler

David G. Winkler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20240050437
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
    Type: Application
    Filed: November 30, 2022
    Publication date: February 15, 2024
    Inventors: Jeffery L. Kutok, David G. Winkler, Vito J. Palombella, Alfredo C. Castro, Catherine A. Evans, Somarajannair Janardanannair, Andre Lescarbeau, Tao Liu, Martin R. Tremblay
  • Antibodies specific for sclerostin and methods for increasing bone mineralization
    Patent number: 11702468
    Abstract: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: July 18, 2023
    Assignee: UCB Pharma, S.A.
    Inventors: David G. Winkler, Jiye Shi, John Latham
  • Heterocyclic compounds and uses thereof
    Patent number: 11541059
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: January 3, 2023
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Jeffery L. Kutok, David G. Winkler, Vito J. Palombella, Alfredo C. Castro, Catherine A. Evans, Somarajannair Janardanannair, Andre Lescarbeau, Tao Liu, Martin R. Tremblay
  • HETEROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20210000837
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
    Type: Application
    Filed: March 11, 2020
    Publication date: January 7, 2021
    Inventors: Jeffery L. Kutok, David G. Winkler, Vito J. Palombella, Alfredo C. Castro, Catherine A. Evans, Somarajannair Janardanannair, Andre Lescarbeau, Tao Liu, Martin R. Tremblay
  • ANTIBODIES SPECIFIC FOR SCLEROSTIN AND METHODS FOR INCREASING BONE MINERALIZATION
    Publication number: 20200231664
    Abstract: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.
    Type: Application
    Filed: August 28, 2019
    Publication date: July 23, 2020
    Inventors: David G. Winkler, Jiye Shi, John Latham
  • Heterocyclic compounds and uses thereof
    Patent number: 10675286
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: June 9, 2020
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Jeffery L. Kutok, David G. Winkler, Vito J. Palombella
  • ANTIBODIES SPECIFIC FOR SCLEROSTIN AND METHODS FOR INCREASING BONE MINERALIZATION
    Publication number: 20180072801
    Abstract: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.
    Type: Application
    Filed: April 20, 2017
    Publication date: March 15, 2018
    Inventors: David G. Winkler, Jiye Shi, John Latham
  • HETEROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20180055852
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
    Type: Application
    Filed: August 9, 2017
    Publication date: March 1, 2018
    Inventors: Jeffery L. Kutok, David G. Winkler, Vito J. Palombella, Alfredo C. Castro, Catherine A. Evans, Somarajannair Janardanannair, Andre Lescarbeau, Tao Liu, Martin R. Tremblay
  • Compositions and methods for increasing bone mineralization
    Patent number: 9791462
    Abstract: A novel class or family of TGF-? binding proteins is disclosed. Also disclosed are assays for selecting molecules for increasing bone mineralization and methods for utilizing such molecules.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: October 17, 2017
    Assignee: UCB PHARMA, S.A.
    Inventors: Mary E. Brunkow, David J. Galas, Brian Kovacevich, John T. Mulligan, Bryan W. Paeper, Jeffrey Van Ness, David G. Winkler
  • Heterocyclic compounds and uses thereof
    Patent number: 9775844
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: October 3, 2017
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Jeffery L. Kutok, David G. Winkler, Vito J. Palombella, Alfredo C. Castro, Catherine A. Evans, Somarajannair Janardanannair, Andre Lescarbeau, Tao Liu, Martin R. Tremblay
  • Antibodies specific for sclerostin and methods for increasing bone mineralization
    Patent number: 9657095
    Abstract: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: May 23, 2017
    Assignee: UCB PHARMA S.A.
    Inventors: David G. Winkler, Jiye Shi, John Latham
  • Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
    Patent number: 9527847
    Abstract: Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating lupus, a fibrotic condition, or inflammatory myopathies and other conditions (e.g., skin conditions).
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: December 27, 2016
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Vito J. Palombella, David G. Winkler
  • COMPOSITIONS AND METHODS FOR INCREASING BONE MINERALIZATION
    Publication number: 20160187357
    Abstract: A novel class or family of TGF-? binding proteins is disclosed. Also disclosed are assays for selecting molecules for increasing bone mineralization and methods for utilizing such molecules.
    Type: Application
    Filed: February 19, 2015
    Publication date: June 30, 2016
    Inventors: Mary E. Brunkow, David J. Galas, Brian Kovacevich, John T. Mulligan, Bryan W. Paeper, Jeffrey Van Ness, David G. Winkler
  • HETEROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20150290207
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
    Type: Application
    Filed: March 18, 2015
    Publication date: October 15, 2015
    Inventors: Jeffery L. KUTOK, David G. WINKLER, Vito J. PALOMBELLA
  • ANTIBODIES SPECIFIC FOR SCLEROSTIN AND METHODS FOR INCREASING BONE MINERALIZATION
    Publication number: 20150191537
    Abstract: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.
    Type: Application
    Filed: March 19, 2015
    Publication date: July 9, 2015
    Inventors: DAVID G. WINKLER, JIYE SHI, JOHN LATHAM
  • Antibodies specific for sclerostin and methods for increasing bone mineralization
    Patent number: 9011856
    Abstract: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.
    Type: Grant
    Filed: November 6, 2012
    Date of Patent: April 21, 2015
    Assignee: UCB Pharma S.A.
    Inventors: David G. Winkler, Jiye Shi, John Latham
  • Antibodies specific for sclerostin and methods for increasing bone mineralization
    Patent number: 8992911
    Abstract: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.
    Type: Grant
    Filed: November 6, 2012
    Date of Patent: March 31, 2015
    Assignee: UCB Pharma S.A.
    Inventors: David G. Winkler, Jiye Shi, John Latham
  • Compositions and methods for increasing bone mineralization
    Patent number: 8986685
    Abstract: Described herein are pharmaceutical compositions comprising an anti-sclerostin antibody and an inhibitor of bone resorption.
    Type: Grant
    Filed: October 4, 2012
    Date of Patent: March 24, 2015
    Assignee: UCB Pharma S.A.
    Inventors: Mary E. Brunkow, David J. Galas, Brian Kovacevich, John T. Mulligan, Bryan W. Paeper, Jeffrey Van Ness, David G. Winkler
  • TREATMENT OF LUPUS, FIBROTIC CONDITIONS, AND INFLAMMATORY MYOPATHIES AND OTHER DISORDERS USING PI3 KINASE INHIBITORS
    Publication number: 20140343057
    Abstract: Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating lupus, a fibrotic condition, or inflammatory myopathies and other conditions (e.g., skin conditions).
    Type: Application
    Filed: July 31, 2014
    Publication date: November 20, 2014
    Inventors: Vito J. PALOMBELLA, David G. WINKLER
  • Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
    Patent number: 8828998
    Abstract: Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating lupus, a fibrotic condition, or inflammatory myopathies and other conditions (e.g., skin conditions).
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: September 9, 2014
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Vito J. Palombella, David G. Winkler